Affiliation:
1. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai 400 019, India
Abstract
:Kinases remain one of the major attractive therapeutic targets for a large number of indications such as cancer, rheumatoid arthritis, cardiac failure and many others. Design and development of kinase inhibitors (ATP-competitive, allosteric or covalent) is a clinically validated and successful strategy in the pharmaceutical industry. The perks come with limitations, particularly the development of resistance to highly potent and selective inhibitors. When this happens, the cycle needs to be repeated, i.e., the design and development of kinase inhibitors active against the mutated forms. The complexity of tumor milieu makes it awfully difficult for these molecularly-targeted therapies to work. Every year newer and better versions of these agents are introduced in the clinic. Several computational approaches such as structure-, ligand-based or hybrid ones continue to live up to their potential in discovering novel kinase inhibitors. New schools of thought in this area continue to emerge, e.g., development of dual-target kinase inhibitors. But there are fundamental issues with this approach. It is indeed difficult to selectively optimize binding at two entirely different or related kinases. In addition to the conventional strategies, modern technologies (machine learning, deep learning, artificial intelligence, etc.) started yielding the results and building success stories. Computational tools invariably played a critical role in catalysing the phenomenal progress in kinase drug discovery field. The present review summarized the progress in utilizing computational methods and tools for discovering (mutant-)selective tyrosine kinase inhibitor drugs in the last three years (2017-2019). Representative investigations have been discussed, while others are merely listed. The author believes that the enthusiastic reader will be inspired to dig out the cited literature extensively to appreciate the progress made so far and the future prospects of the field.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Reference71 articles.
1. Do, K.T.; Kummar, S. Therapeutic targeting of cancer cells: era of molecularly targeted agents. In: Abeloff’s Clinical Oncology, 6th ed; Niederhuber, J.E.; Armitage, J.O.; Kastan, M.B.; Doroshow, J.H.; Tepper, J.E. Eds.; Elsevier Inc.: Amsterdam. 2020,420-430.e2
2. Duong-Ly, K.C.; Peterson, J.R. The human kinome and kinase inhibition. Curr. Protoc Pharmacol. 2013,60(1),1-14. http://dx.doi.org/10.1002/0471141755.ph0209s60
3. Sawyers.; C.L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 2002,12(1),111-115. http://dx.doi.org/10.1016/S0959-437X(01) 00273-8 PMID: 11790564
4. Schlessinger.; J. Cell signaling by receptor tyrosine kinases. Cell. 2000,103(2),211-225. http://dx.doi.org/10.1016/S0092-8674(00) 00114-8 PMID: 11057895
5. Du,Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer. 2018,17(1),58. http://dx.doi.org/10.1186/s12943-018-0782-4 PMID: 29455648
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献